|
|
Profile
|
Delegates :
Kazuaki Kanai |
|
Incorporated :
April 8 , 2005 |
Paid in Capital :
100 Million yen |
Employees :
22 人 |
Address :
Life Science Research Center 4-1 1-1-43, Suehiro-cho, Tsurumi, Yokohama KANAGAWA
〒230-0045
|
TEL/FAX :
+81-45-633-4327 / +81-45-633-4329 |
URL：
http://www.jitsubo.com |
Attachment :
|
Mission/Background :
Jitsubo is a privately-held biopharmaceutical company, employing our proprietary Molecular Hiving and Peptune platform for the discovery and development of new peptide-based drugs.
Molecular Hiving is a new generation peptide manufacturing technology enabling to provide the peptide drug substances in a sufficient quality and cost with short lead time.
By utilizing Peptune technology, peptides receive better therapeutic property. This technology also enables multi-functionalization of the peptide such as attaching targeting material with no loss of expected original efficacy.
Jitsubo creates a new value for peptide based drugs with process and product innovation.
|
|
Technology & Business
|
Molecular Hiving is a new liquid phase based peptide synthesis technology using hydrophobic tag. This technology integrates the advantages of both liquid phase method and solid phase method and made it good hybrid.
Peptune is a new type of chemical engineering technology introducing artificial bridge into peptides. This technology provides derivatives with a vast of steric constraint and conjugates with other functional moiety on bridge head position. The unprecedented chemical capability contributes rapid and efficient optimization of therapeutic property.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Co-development of peptide generic products
|
Others
|
Jitsubo looks for a pharmaceutical company to commercialize the peptide generic drugs under development in-house.
|
Finding a partner for Jitsubo's candidate products
|
Co-development of alternative administration products
|
Others
|
Jitsubo looks for a collaboration opportunity with delivery tech. co. to develop high compliance products.
|
Finding a partner for Jitsubo's candidate products
|
Technology licensing
|
Others
|
Jitsubo looks for out-licensing opportunity of Molecular Hiving.
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Jitsbo is promoting research collaboration with Heptares Therapeutics (UK) to develop novel peptide candidates designed to target a G protein-coupled receptor implicated in severe gastro-intestinal disorders.
|
|
Alliance strategy
|
1. Co-develop and licensing the peptide generic products or DS
2. Co-develop 505(b)(2) products with non-invasive administration
3. Licensing the MH technology based on your drug substances
|
|
|